Drugs / Anflu
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02640989 | Oct 2014 | influenza | Center for Disease Prevention and Control of Beijing Military Region | Completed | No outcome recorded |
| Phase 4 | NCT02269852 | Dec 2013 → Apr 2014 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01051349 Background | Mar 2010 → Aug 2016 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00556062 Comparator | Sep → Nov 2007 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anflu | “To evaluate the safety and immunogenicity of the three consecutive lots of an seasonal split influenza vaccine Anflu in adults, a randomized, double-blind and controlled...” NCT00556062 ↗ |
| Known as | trivalent seasonal influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02269852 ↗ |
| Modality | Vaccine | “trivalent seasonal influenza vaccine” NCT01051349 ↗ |
| Route | Intramuscular | “Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0” NCT02640989 ↗ |